Actively Recruiting
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Led by Northwestern University · Updated on 2026-05-01
30
Participants Needed
1
Research Sites
302 weeks
Total Duration
On this page
Sponsors
N
Northwestern University
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.
CONDITIONS
Official Title
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed WHO grade 2-4 glioma, IDH wild type
- Established diagnosis of recurrent glioblastoma
- For groups 1 and 2: recurrent glioblastoma
- For group 3: surgically amenable recurrent glioblastoma
- Stable or decreasing corticosteroid dose equivalent to 64 6 mg dexamethasone for at least 7 days before registration
- Disease progression after standard or investigational first-line therapy including radiotherapy with or without temozolomide
- Able to undergo contrast-enhanced MRI
- Age 18 years or older
- Karnofsky performance status of 64 70
- Leukocytes 64 3,000/mcL
- Absolute neutrophil count 64 1,500/mcL
- Hemoglobin 64 8 g/dL (transfusion allowed within 7 days)
- Platelets 64 100,000/mcL (transfusion or growth factor allowed within 7 days)
- Total bilirubin 64 2 times institutional upper limit of normal
- AST/ALT 64 3 times institutional upper limit of normal
- Creatinine 64 1.5 times institutional upper limit of normal
- INR 64 1.5 times upper limit of normal
- PT/PTT 64 1.5 times upper limit of normal
- Cardiac function classified as New York Heart Association class 2B or better
- Use of two forms of contraception if of child-bearing potential or agree to abstinence
- Willing and able to comply with study protocol and provide informed consent
You will not qualify if you...
- Prior or concurrent malignancy that may interfere with study treatment or safety
- Receiving other investigational agents (except COVID-19 vaccines or treatments as allowed)
- Less than required time since last cytotoxic therapy (e.g., temozolomide, lomustine, targeted agents, bevacizumab)
- History of allergic reactions to compounds similar to temozolomide or triapine
- Spinal cord or diffuse leptomeningeal disease spread
- History of G6PD deficiency or hemolytic disorders
- Uncontrolled illness including epilepsy, infections, immunodeficiency, psychiatric illness, or other conditions limiting compliance or safety
- Pregnant or nursing
- Unable to swallow or absorb oral medication
- Known history of HIV, hepatitis B, or hepatitis C infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Northwestern University
Chicago, Illinois, United States, 60611
Actively Recruiting
Research Team
S
Study Coordinator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here